NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Crinetics Pharmaceuticals, Inc. (CRNX) Stock Analysis

Crinetics Pharmaceuticals, Inc. (CRNX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

CRNX

$84.95

$0.00 (0.00%)

Sep 2, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CRNX with… →

CRNX Key Statistics

As of Sep 2, 2026
Trading
Open
$84.95
Previous Close
$84.95
52-Week Range
32.30–85.01
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.09
Valuation
Market Cap
$9.01B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
213.80
EPS (ttm)Profit attributable to each share over the last twelve months.
−5.05
Financials (FY)
Revenue (FY)
$7.70M+640.71%
Net Income (FY)
−$465.32M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
106.10M
1-Year Return
+155.11%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
4.24M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CRNX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+82.49%
2025−8.96%
2024+43.70%
2023+94.43%
2022−35.59%
2021+101.35%
2020−43.76%
2019−16.34%
2018 (partial year)+22.36%

As of September 2, 2026.

CRNX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$7.70M−$465.32M−6046.2%
2024$1.04M−$298.41M−28720.7%
2023$4.01M−$214.53M−5345.9%
2022$4.74M−$163.92M−3460.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$7.70M$6.62M−$516.77M−$465.32M−6046.2%
2024$1.04M$1.04M−$338.85M−$298.41M−28720.7%
2023$4.01M$4.01M−$222.61M−$214.53M−5345.9%
2022$4.74M—−$167.88M−$163.92M−3460.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CRNX Valuation vs Biotechnology Median

Median of 656 stocks
MetricCRNXBiotechnology medianvs median
P/S ratio213.8015.2614.0x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Crinetics Pharmaceuticals, Inc. (CRNX) is capitalised at $9.01B on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 594.

The most recent close on file for CRNX is $84.95, dated September 2, 2026. The close was unchanged from the previous session. Over the past 52 weeks the price has ranged from $32.30 to $85.01. The latest close sits 163% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $7.70M. That is +640.71% against the prior fiscal year, when revenue was $1.04M. The same year closed with a net loss of $465.32M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −5.05.

Across the 4 fiscal years on file, revenue moves from $4.74M in 2022 to $7.70M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 213.8 times revenue. On price-to-sales that is 14 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The reported beta is 0.09. Daily returns over the trailing 8 years annualize to a volatility of 73.26%. Over the trailing twelve months the price has returned +155.11%. Measured over 5 years, that is +28.44% a year compounded.

Growth & Income

The record shows no dividend for CRNX.

2026 is still running; the price is +82.49% year to date. Across the complete calendar years on file, 2021 returned +101.35% and 2020 returned −43.76%. Of the 7 complete calendar years on file, 3 finished higher.

Peer Comparison

Crinetics Pharmaceuticals, Inc. (CRNX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Crinetics Pharmaceuticals, Inc. CRNX $9.01B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Crinetics Pharmaceuticals, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 2, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and cushing's disease; and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease; and SST3 Agonist program for the treatment of polycystic kidney disease, as well as Oral GLP-1 and Oral GIP nonpeptides for the treatment of obesity. The company has an agreement with Sanwa Kagaku Kenkyusho Co., Ltd to develop and commercialize Paltusotine in Japan, and Cellular Longevity, Inc. to develop and commercialize CRN01941, a somatostatin receptor type 2 agonist. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Visit website →